PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience. (Q40040709)

From Wikidata

Jump to navigation Jump to search

scientific article published on 9 June 2012

Language	Label	Description	Also known as
English	PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.	scientific article published on 9 June 2012

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22687565%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22687565%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Catherine Sánchez

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22687565%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Christian G Ramos

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22687565%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Raul Valdevenito

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22687565%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Ivonne Vergara

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22687565%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Patricio Anabalon

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22687565%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Juan Fulla

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22687565%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

9 June 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22687565%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Urologic Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22687565%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

31

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22687565%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22687565%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1522-1526

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22687565%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Screening and prostate-cancer mortality in a randomized European study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

Contemporary role of prostate cancer gene 3 in the management of prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

The use of PCA3 in the diagnosis of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

PCA3: a molecular urine assay for predicting prostate biopsy outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

American Cancer Society guideline for the early detection of prostate cancer: update 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

Urinary prostate cancer 3 test: toward the age of reason?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.05.002

7 January 2021

Identifiers

10.1016/J.UROLONC.2012.05.002

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22687565%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22687565%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40040709&oldid=1481777765"